

# Exchange traded investment fund

## FinEx Developed Markets ex US UCITS ETF (USD)



07/29/2025

### USD share class

BLOOMBERG:

**SXUS200N index**

USD share class

**(ISIN: IE00BMDKNM37)**

### Index Information

Index Ticker (Bloomberg)

**SXUS200N index**

Index Provider

**Solactive AG**

Index Currency

**USD**

### Key Information

Product Name	FinEx Developed Markets ex US UCITS ETF (USD)
ISIN	IE00BMDKNM37
Issuer	FinEx Funds ICAV
Inception Date	04/08/2021
Fund Domicile	Ireland
UCITS V Compliant	Yes
Fund Manager	KBA Consulting Management Limited (Great Britain)
Base Currency	USD
Total Expense Ratio	0.90%
Reference Index	Solactive GBS Developed Markets ex United States 200 USD Index NTR
Custodian/Administrator	Citi Depository Services (Ireland)/Citibank Europe
EUSD Taxation	Out Of Scope
Replication Method	Full replication
Reporting Frequency	Semi-Annually
Close of Fiscal Year	30-September
Fund Auditor	Grant Thornton
Trading Taxes	No UK Stamp duty or SDRT
Currency Hedging	No
Minimum Purchase	1 share
NAV per share DD 07/28/2025	1.354569 USD
Shares in Issue	34,300,000
Total Fund Assets	46,461,720.74 USD


### Investment Objective

The Fund aims to track the performance of the Solactive GBS Developed Markets ex United States 200 USD Index NTR (the "Index") before charges are applied to the Fund.

### Trading Information

Stock Exchange	Bloomberg Ticker	Bloomberg INAV
Irish Stock Exchange	FXDM ID	FXDMUSIV Index

### Share class return for (USD, %)\*:




\*The yield is indicated in the fund's currency (U.S. dollar)


### Contacts

KBA Consulting Management Limited  
35 Shelbourne Road  
Ballsbridge  
Dublin  
Ireland, D04 A4E0

## Sector Allocation



## Geographic Allocation



## TOP 10 holdings

Security	ISIN	Currency	Weight
SAP ORD	DE0007164600	EUR	2.006%
ASML HOLDING NV	NL0010273215	EUR	1.891%
NESTLE SA-REG	CH0038863350	CHF	1.651%
ROCHE HLDG-GENUS	CH0012032048	CHF	1.586%
NOVARTIS AG-REG	CH0012005267	CHF	1.568%
HSBC HOLDINGS ORD	GB0005405286	GBP	1.560%
ASTRAZENECA ORD	GB0009895292	GBP	1.496%
NOVO NORDISK A/S-B	DK0062498333	DKK	1.494%
SHELL PLC-NEW	GB00BP6MXD84	GBP	1.465%
TOYOTA MOTOR ORD	JP3633400001	JPY	1.383%

## Authorized participants

### Goldenberg Hehmeyer LLP

25 Canada Square, Canary Wharf  
London E14 5LB  
Tel: +44 (0) 207 390 33 35

### FinEx Capital Management LLP

25 Green Street,  
London W1K 7AX  
Tel: +44 (0) 20 7663 3300  
Email: info@finxcapital.com

### LLC C SAV Capital

Khoroshevskoye highway, Moscow, 125284, Russia  
room 12/1, 32A,  
Tel: +7 495 568-12-19  
Email: a.popovina@sav.capital

### Jane Street

10 Chiswell Street  
London EC1Y 4UQ  
Tel: +44 (0) 203 100 34 00

### Barclays Capital Securities Limited

5 North Colonnade London E14 4BB  
Tel: +44 (0) 203 134 52 78

### Cifra broker LLC

18th floor, 1st Krasnogvardeysky proezd 15,  
Moscow, 123112, Russia  
Tel: +7 (495) 783-91-73  
Email: info@cifra-broker.ru

Further information about FinEx Funds ICAV can be found in the prospectus and the supplement to the prospectus of the fund which is available at FinEx Group's website [www.FinExETF.com](http://www.FinExETF.com)

### GENERAL DISCLAIMER

Investment in the products mentioned in this document may not be suitable for all investors. Past performance is not a guide to future performance and should not be the sole factor of consideration when selecting a product. The price of the investments may go up or down and the investor may not get back the amount invested. Your income is not fixed and may fluctuate. The value of investments involving exposure to foreign currencies can be affected by exchange rate movements. We remind you that the levels and bases of, and reliefs from, taxation can change. FinEx has not considered the suitability of this investment against your individual needs and risk tolerance. The data displayed provides summary information, investment should be made on the basis of the relevant Prospectus which is available from your Broker, Financial Adviser or FinEx Investment Management LLP. We recommend you seek independent professional advice prior to investing. In respect of the products mentioned this document is intended for information purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to buy the securities described within. This document may not be distributed without authorisation from FinEx Investment Management LLP.

FinEx Investment Management LLP, which is authorised and regulated by the Financial Conduct Authority ('FCA'), having its registered office at 4, Hill Street, London, W1J 5NE, England, has issued this document. FinEx ETFs constitute exchange traded funds issued by an Irish domiciled company, FinEx Funds ICAV established under Irish law (the "Fund"). FinEx Funds ICAV (the "company") is an open-ended investment company with variable capital having segregated liability between their funds organised under the laws of Ireland and authorised by the Financial Regulator.

For professional investors in the UK: Please note that the Fund is not registered in the United Kingdom. Most of the protections provided by the UK regulatory system do not apply to the operation of the Company, and compensation will not be available under the UK Financial Services Compensation Scheme on its default. The Company is a recognised scheme for the purposes of the Financial Services and Markets Act 2000.

This document is not, and under no circumstances is to be construed as, an advertisement, or any other step in furtherance of a public offering of shares in the United States or Canada. This document is not aimed at persons who are resident in the United States, Canada or any province or territory thereof, where the Companies are not authorised or registered for distribution and where no prospectus for the Companies has been filed with any securities commission or regulatory authority. The Company may not be acquired or owned by, or acquired with the assets of, an ERISA Plan.

Barclays is a trademark of Barclays Bank PLC and is used by FinEx under licence. The Fund is not sponsored, endorsed, sold or promoted by Barclays and Barclays makes no representation regarding the advisability of investing in the Fund.